| Literature DB >> 28459811 |
Bin Jia1, Fengbo Zhang2, Ying Lu3, Wenbao Zhang1, Jun Li2, Yuexin Zhang1, Jianbing Ding1,4.
Abstract
BACKGROUND: This study aims to analyze the clinical characteristics and treatment outcomes of 590 patients with brucellosis in Xinjiang, China. METHODOLOGY AND PRINCIPALEntities:
Mesh:
Substances:
Year: 2017 PMID: 28459811 PMCID: PMC5426775 DOI: 10.1371/journal.pntd.0005577
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Baseline demographics of patients with brucellosis.
| Number of patients | 590 |
|---|---|
| Male | 455 (77.1%) |
| Female | 135 (22.9%) |
| Age (Average, years) | 44.24 ±15.83 |
| 3–18 years | 59 (10%) |
| 19–45 years | 292 (49.5%) |
| 46–60 years | 169 (28.6%) |
| 61–75 years | 70 (11.9%) |
| Staging | |
| Acute | 316 (53.6%) |
| Subacute | 136 (23.1%) |
| Chronic | 127 (21.5%) |
| Asymptomatic | 11 (1.86%) |
| Ethnicity | |
| Han | 271 (45.9%) |
| Uighur | 189 (32%) |
| Kazak | 98 (16.6%) |
| Xibe | 16 (2.71%) |
| Mongolia | 9 (1.53%) |
| Hui | 7 (1.19%) |
| Medical history | |
| Exposure and farming of cattle or sheep | 357 (60.5%) |
| Consumption history of raw meat or dairy | 145 (24.6%) |
| None | 88 (14.9%) |
| History of complications | |
| Yes | 180 (30.5%) |
| No | 410 (69.5%) |
Clinical characteristics of patients with brucellosis.
| Symptoms | Number of patients | % |
|---|---|---|
| Fatigue | 537 | 91 |
| Hyperhidrosis | 520 | 88.1 |
| Fever | 513 | 86.9 |
| Joint pain | 478 | 81 |
| Back pain | 322 | 54.6 |
| Anorexia | 270 | 45.8 |
| Weight loss | 179 | 30.3 |
| Nausea | 78 | 13.2 |
| Headache | 46 | 7.80 |
| Stomachache | 21 | 3.56 |
| Physical examinations | ||
| Fever | 300 | 50.8 |
| Enlarged liver | 176 | 29.8 |
| Enlarged spleen | 154 | 26.1 |
| Scrotal swelling | 15 | 2.54 |
| Jaundice | 3 | 0.51 |
| Osteoarticular involvement | 137 | 23.2 |
| Genitourinary system involvement | 15 | 2.54 |
| Cardiovascular involvement | 10 | 1.69 |
| Pneumonia | 6 | 1.02 |
| Skin involvement | 4 | 0.68 |
| Nervous system involvement | 1 | 0.17 |
Laboratory results of patients with brucellosis.
| Number of patients | % | |
|---|---|---|
| Anemia (Hb: male <14 mg / dl, Female < 12 mg / dl) | 267 | 45.3 |
| Lymphocytosis (lymphocytes > 45%) | 197 | 33.4 |
| Increased Transaminase (alanine/aspartame > 50 U / L) | 179 | 30.3 |
| Thrombocytopenia (platelets <15 × 104 / mm3) | 117 | 19.8 |
| Leukocytosis (white blood cells > 10,000 / mm3) | 91 | 15.4 |
| Leukopenia (white blood cells < 4,000 / mm3) | 55 | 9.3 |
| Elevated ESR > (20 mm/h) | 382 | 64.7 |
| Increased CRP(> 8 mg/l) | 261 | 44.2 |
| Others | ||
| Positive amber red plate test | 590 | 100 |
| Positive standard tube agglutination test (≥ 1: 100) | 583 | 98.8 |
| Positive culture (positive / all cases) | 173/505 | 34.3 |
| Blood culture | 159/468 | 34.0 |
| Bone marrow | 12/31 | 38.7 |
| Cardiac valve | 2/3 | 66.7 |
| Synovial fluid | 0/2 | 0 |
| Cerebral fluids | 0/1 | 0 |
Note: Hb, hemoglobin; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
Treatment plan, follow-up and prognosis.
| Number of cases (%) | Treatment duration (weeks) | Number of relapses (%) | Number of death | |
|---|---|---|---|---|
| All patients in follow-up | 468 | 28 (5.98) | 6 | |
| Treatment plan (patients without complications) | 288 (61.5) | 10 (3.47) | 1 | |
| Doxycycline + rifampicin | 148 | 6–12 | 3 (2.03) | - |
| Doxycycline + levofloxacin | 69 | 6–12 | 3 (4.35) | - |
| Doxycycline + streptomycin | 51 | 6–12 | 2 (3.92) | - |
| Doxycycline + ciprofloxacin | 9 | 6–12 | 1 (11.1) | 1 |
| Doxycycline + ceftriaxone | 11 | 6–12 | 1 (9.10) | - |
| Treatment plan (patients with complications) | 180 (38.5) | 17 (9.44) | - | |
| Bone and joint complications | 137 | 14 (10.2) | - | |
| Doxycycline + rifampicin | 55 | 8–12 | 4 (7.27) | - |
| Doxycycline + streptomycin | 11 | 8–12 | 2 (18.2%) | 1 |
| Doxycycline + rifampin + levofloxacin | 39 | 8–12 | 2 (5.13%) | - |
| Doxycycline + moxifloxacin | 17 | 8–12 | 3 (17.6%) | - |
| Rifampin + levofloxacin | 15 | 8–12 | 3 (20) | - |
| Endocarditis Complications | 10 (2.14) | 4 | ||
| Doxycycline + rifampicin | 1 | 8–12 | 2 | 2 |
| Doxycycline + rifampicin + valve replacement | 1 | 8–12 | 0 | - |
| Doxycycline + rifampicin + ceftriaxone | 2 | 8–12 | 1 | 1 |
| Doxycycline + rifampin + ceftriaxone + valve replacement | 3 | 8–12 | 0 | - |
| Doxycycline + rifampin + levofloxacin | 1 | 8–12 | 1 | 1 |
| Doxycycline + rifampicin + levofloxacin + valve replacement | 2 | 8–12 | 0 | - |
Note
a. There were significant differences of relapse rate between group with/ without osteoarticular complications (p < 0.05)
b. There were significant differences of relapse rate in doxycycline + streptomycin group between those with/ without osteoarticular complications (p < 0.05)
c. The relapse rate was higher in patients with osteoarticular complications receiving 2-drug regimen, compared with those receiving 3-drug regimen (p < 0.05).